Raymond James raised the firm’s price target on DexCom to $160 from $151 and keeps a Strong Buy rating on the shares. Raymond James was hoping for a bit more upside, but DexCom added a record number of new users in Q1, which is the leading indicator of future revenue growth, and lifted the low end of its revenue guidance, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DXCM: